Osugacestat (AL101, BMS-906024)
ACCURACY
Ayala Pharmaceuticals · Phase 2 · Completed · Enrollment 87
| Arm | Reported safety |
|---|---|
| AL101 4 mg | patients with serious adverse events: 23 patients (of 45), final |
| AL101 6 mg | patients with serious adverse events: 26 patients (of 42), final |
A count stays a count. This page does not turn a count into a percent.